Curriculum Vitaes
Profile Information
- Affiliation
- professor, School of Medicine, Department of Respiratory Medicine, Fujita Health University
- Degree
- 医学博士(名古屋大学)
- J-GLOBAL ID
- 200901040286800734
- researchmap Member ID
- 6000001873
Research Areas
1Papers
239-
Annals of the American Thoracic Society, 22(4) 609-611, Apr, 2025
-
Cytopathology, in press, Feb 7, 2025 Peer-reviewed
-
Sleep and biological rhythms, 23(1) 29-37, Jan, 2025The purpose of this study was to evaluate how the first oral administration of suvorexant affects PSG results in patients with severe obstructive sleep apnea (OSA). Single-center, prospective study conducted in a nonrandomized, uncontrolled, unblinded fashion. Undiagnosed 64 patients with suspected OSA underwent first-night PSG, and 30 patients with severe OSA (Apnea Hypopnea Index [AHI] ≥ 30 events/h) underwent second-night PSG testing after administration of 15 mg suvorexant. The change in AHI between the first and second nights was not significant, although the upper limit of the 95% confidence interval for the mean difference in AHI was high at 5.987.The mean duration of apnea on the second night was significantly prolonged compared to that on the first night, but there were no significant differences n 3% oxygen desaturation index, saturation of percutaneous oxygen<90% time. On the second night, total sleep time was significantly prolonged, mid-night awakenings decreased, REM sleep percentage increased, and REM latency was shorter. Because the environment for PSG testing is very different from the patient's home and many patients have difficulty sleeping, there are clinical cases in which PSG is performed with sleep medication. In this study, PSG after oral administration of 15 mg of suvorexant on the second night showed no significant difference or clear trend in AHI. However, the upper limit of the 95% confidence interval for the mean difference in AHI was greater than 5, suggesting that suvorexant may exacerbate AHI, even with the first administration.
-
BMC pulmonary medicine, 24(1) 632-632, Dec 26, 2024BACKGROUND: The increasing prevalence of lung cancer in the elderly population necessitates a closer evaluation of diagnostic and therapeutic approaches. This study aimed to compare the safety and diagnostic efficacy of transbronchial lung cryobiopsy (TBLC) between patients ≥ 80 years and younger patients. METHODS: A retrospective review was conducted of 96 patients diagnosed with peripheral lung cancer who underwent TBLC between April 2021 and October 2023. The patients were categorized into two groups: the elderly group (age ≥ 80 years, n = 20) and younger group (age < 80 years; n = 76). Data regarding the biopsy yield, complications, and feasibility of molecular analyses were collected and analyzed. RESULTS: The diagnostic yield of TBLC was comparable between the elderly and younger groups (95% vs. 89.5%, p = 0.679). Biomarker testing, including programmed death-ligand 1 expression and genetic mutations, were feasible in all cases diagnosed with cancer using TBLC samples. No significant differences were observed in major complications such as pneumothorax or bleeding. CONCLUSIONS: TBLC was found to be a safe and effective diagnostic tool for peripheral lung cancer in elderly patients and provided adequate samples for molecular testing. Since the complication rates did not significantly differ between the two age groups, age alone should not be considered a contraindication for the procedure.
-
Expert opinion on drug safety, Dec 17, 2024BACKGROUND: Immune checkpoint inhibitors (ICIs) play a central role in cancer immunotherapy. However, the occurrence of immune-related adverse events, especially ICI-induced interstitial lung disease (ICI-ILD), is life-threatening and affects the effectiveness of ICI treatment. This study aimed to explore potential drugs to mitigate ICI-ILD occurrence using data from the Japanese Adverse Drug Event Report (JADER) and the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS [JAPIC AERS]). RESEARCH DESIGN AND METHODS: We investigated concomitant drugs that reduce ILD associated with four ICIs - nivolumab, pembrolizumab, atezolizumab, and durvalumab - across the JADER and FAERS databases. Subsequently, the identified common concomitant drugs that reduce the occurrence of ICI-ILD were detected and analyzed. RESULTS: We found omega-3 fatty acids, loperamide, and amlodipine as common concomitant drugs that reduced ICI-ILD occurrence in both the JADER and FAERS databases. Omega-3 fatty acids reportedly have many effects in animal models of drug-induced ILD, including their association with ILD in humans and anti-inflammatory effects against ICI-ILD. However, loperamide and amlodipine reportedly have minimal effects against ILD, thereby necessitating further evaluation. CONCLUSION: Omega-3 fatty acids have emerged as potential agents for reducing ICI-ILD occurrence, as evidenced by findings from two different pharmacovigilance databases.
Misc.
209-
BMC PULMONARY MEDICINE, 14 14-14, Feb, 2014 Peer-reviewed
-
PLOS ONE, 8(11) e81133, Nov, 2013 Peer-reviewed
-
GERIATRICS & GERONTOLOGY INTERNATIONAL, 13(4) 986-992, Oct, 2013 Peer-reviewed
-
Allergology international : official journal of the Japanese Society of Allergology, 62(3) 367-73, Sep, 2013 Peer-reviewedBACKGROUND: Although a challenge test using non-steroidal anti-inflammatory drugs (NSAIDs) is crucial for diagnosis of aspirin-induced asthma (AIA), it also has drawbacks in terms of possible side effects. Therefore, alternative in-vitro diagnostic methods for AIA are awaited. METHODS: Nineteen stable non-AIA patients (9 males and 10 females; mean age, 49.4 ± 4.8 years), and 20 AIA patients (9 males and 11 females; mean age, 51.1 ± 4.8 years) were enrolled in this study. CD11b and CD16 expressions on the peripheral-blood granulocytes after administration of aspirin and different concentrations of PGE2 in vitro were examined using flowcytometry. RESULTS: Aspirin induced a significant increase in CD11b expression on eosinophils (CD16 negative granulocytes) in 19 AIA patients and one non-AIA patient. Increase in CD11b expression on eosinophils by aspirin administration was suppressed by PGE2 in a dose-dependent manner. CONCLUSIONS: The measurement of CD11b expression on peripheral-blood eosinophils showed very high sensitivity and specificity of (-95%) in diagnosing AIA. Although this method requires laboratory facilities for flowcytometry, it may be very useful in diagnosis of AIA without side effects. In addition, PGE2 may be involved in regulation of CD11b expression on eosinophils by aspirin administration.
-
European journal of heart failure, 15(9) 1003-10, Sep, 2013 Peer-reviewedAIMS: We examined whether the severity of central sleep apnoea (CSA) and the level of C-reactive protein are associated with the prevalence and complexity of arrhythmias, and whether these factors contribute to increased risk of nocturnal sudden death. METHODS AND RESULTS: We prospectively examined 178 patients (age 70 ± 1 years) who were admitted to our hospital due to worsening heart failure. We recorded a simultaneous overnight cardiorespiratory polygraph and Holter ECG. Obstructive sleep apnoea was excluded and patients were dichotomized based on the median value of the central apnoea index (CAI) of 7.5/h. The prevalence and complexity of arrhythmias were compared between daytime (06:00 h to 15:00 h) and night-time (21:00 h to 06:00 h). A multivariate logistic regression analysis revealed that the CAI was associated with prevalence of atrial fibrillation (AF) [odds ratio 1.03, 95% confidence interval (CI) 1.02-2.51)] and sinus pause during the night-time period (1.12, 95% CI 1.08-1.35). The CAI and C-reactive protein were independently associated with non-sustained ventricular tachycardia during both daytime (1.22, 95% CI 1.00-6.92; and 5.82, 2.58-56.1, respectively) and night-time periods (3.57, 95% CI 1.06-13.1; and 10.7, 3.30-44.4, respectively). During a mean follow-up period of 22 months, 30 (17%) patients had cardiovascular deaths and the CSA was an independent predictor (hazard ratio 1.29, 95% CI 1.16-2.32); only 5 (2.8%) of them died due to ventricular tachyarrhythmia, occurring during wakefulness. CONCLUSIONS: We demonstrated that the severity of CSA and C-reactive protein levels are independently associated with the prevalence and complexity of arrhythmias. CSA was associated with increased mortality risk, but it was not related directly to nocturnal death due to ventricular tachyarrhythmia.
-
Respirology, 18(2) 340-347, Feb, 2013 Peer-reviewed
-
The Journal of the Japan Society for Respiratory Endoscopy, 35(2) 188-192, 2013 Peer-reviewedBackground. Although most cystic mediastinal diseases are benign, it should be noted that malignant tumor could appear as a cystic lesion. We report a case of mediastinal parathyroid cyst with a brown tumor of the rib, initially suspected to be a malignant tumor with bone metastasis. Case. A 63-year-old man was hospitalized because of dysphagia and hoarseness. A PET-CT showed a cystic mass in the upper mediastinum and an osteolytic lesion in the left rib accompanied with increased uptake of FDG. We performed EBUS-TBNA of the mediastinal mass and found no malignant findings. Blood examinations also revealed no abnormalities. Biopsy of the rib lesion revealed the possibility of a brown tumor due to hyperparathyroidism and blood examinations revealed a high blood parathyroid hormone. The mediastinal parathyroid cyst was resected and the bone lesion reduced in size. Conclusion. Ectopic mediastinal parathyroid cyst with rib brown tumor is very rare. When we see a tumorous legion with hypercalcemia, parathyroid hormone measurements would be performed to rule out ectopic parathyroid tumors.
-
平成24年度 厚生労働科学研究費補助金 難治性疾患等克服研究事業 免疫アレルギー疾患等予防・治療研究事業 研究報告書(免疫アレルギー疾患分野), 288-292, 2013
-
肺癌, 53(4) 318-323, 2013 Peer-reviewed
-
IMMUNOGENETICS, 65(1) 17-24, Jan, 2013 Peer-reviewed
-
INTERNAL MEDICINE, 52(13) 1473-1478, 2013 Peer-reviewed
-
Respiration; international review of thoracic diseases, 86(3) 252-3, 2013 Peer-reviewed
-
MOLECULAR CARCINOGENESIS, 51(5) 400-410, May, 2012 Peer-reviewed
-
INTERNATIONAL JOURNAL OF COMPUTER ASSISTED RADIOLOGY AND SURGERY, 7(3) 359-369, May, 2012 Peer-reviewed
-
平成23年度総括・分担研究報告書、厚生労働科学研究・免疫アレルギー疾患等予防・治療研究事業, 23-26, 2012
-
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 45(4) 684-691, Oct, 2011 Peer-reviewed
-
ANTI-CANCER DRUGS, 22(8) 811-816, Sep, 2011 Peer-reviewed
-
NAGOYA JOURNAL OF MEDICAL SCIENCE, 73(3-4) 69-78, Aug, 2011 Peer-reviewed
-
Virtual bronchoscopy-guided transbronchial biopsy for aiding the diagnosis of peripheral lung cancerEUROPEAN JOURNAL OF RADIOLOGY, 79(1) 155-159, Jul, 2011 Peer-reviewed
-
Am J Respir Cell Mol Biol, 44(5) 614-620, 2011 Peer-reviewed
-
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 15(6) 583-587, Dec, 2010 Peer-reviewed
-
CANCER SCIENCE, 101(12) 2601-2605, Dec, 2010 Peer-reviewed
-
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 43(2) 161-172, Aug, 2010 Peer-reviewed
-
EUROPEAN JOURNAL OF PHARMACOLOGY, 635(1-3) 204-211, Jun, 2010 Peer-reviewed
-
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 339(1) 41-48, Jan, 2010 Peer-reviewed
-
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 30(10) 1019-1021, Oct, 2009 Peer-reviewed
-
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 297(3) L420-L431, Sep, 2009 Peer-reviewed
-
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 40(5) 536-542, May, 2009 Peer-reviewed
-
Chest, 135(3) 633-640, Mar, 2009 Peer-reviewed
-
別冊日本臨床 新領域別症候群シリーズ, 10 196-198, 2009
-
LUNG CANCER, 63(1) 72-76, Jan, 2009 Peer-reviewed
-
肺癌, 48(7) 868-868, Dec 20, 2008
-
肺癌, 47(5) 491-491, Oct 10, 2007(一般演題(口演)9 癌性胸膜炎・心膜炎,第48回日本肺癌学会総会号)
Books and Other Publications
2Presentations
79Research Projects
16-
Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Apr, 2025 - Mar, 2028
-
Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Apr, 2023 - Mar, 2026
-
科学研究費助成事業, 日本学術振興会, Apr, 2023 - Mar, 2026
-
科学研究費助成事業, 日本学術振興会, Apr, 2022 - Mar, 2025
-
Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Apr, 2021 - Mar, 2024
その他教育活動上特記すべき事項
1-
件名(英語)第48回医学教育ワークショップ終了年月日(英語)2013/08/18概要(英語)「臨床実習学習成果の設定」に参加した。